![]() We will also continue to assess external opportunities that could help sustain long term growth and continue the Companys path towards profitability.įourth Quarter 2011 and Recent Highlights:īeginning January 1, 2012, new XIAFLEX-specific Current Procedural Terminology (CPT ®) codes became available for use in the U.S. In 2012, we will continue to focus on commercial execution and on developing XIAFLEX for the treatment of multiple potential indications with a particular focus on achieving the near-term development milestones for Peyroniesĭisease. ![]() XIAFLEX ® use for Dupuytrens contracture, and supported our EU partner, Pfizers, launch of XIAPEX ® for Dupuytrens contracture in nine EU markets, said Adrian Adams, Chief Executive Officer and President We achieved record revenues for the company and Testim ®, grew U.S. In 2011, Auxilium made continued progress toward our vision of becoming a rapidly growing, profitable and sustainableīiopharmaceutical company. For the full year 2011, Auxiliums net loss was $(32.9) million, or $(0.69) per share, compared to a net loss of $(51.2) million, or $(1.08) per share, for the full year 2010. For the full year 2011, net revenues totaled $264.3 million compared to net revenues of $211.4 million for the full year 2010, an increase of 25%.įor the quarter ended December 31, 2011, Auxilium reported a net loss of $(11.9) million, or $(0.25) per share, compared to a net loss of $(16.4) million, or $(0.34) per share, in the fourth quarter For the quarter ended December 31, 2011, Auxilium reported record net revenues of $73.3 million compared to net revenues of $61.8 million in theįourth quarter of 2010, an increase of 19%. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |